Call for session topics and speakers for the AusBiotech 2026 Program
For decades, AusBiotech has united Australia’s life sciences sector, connecting people, ideas, and opportunities. Our flagship conference is the biggest week in biotech and life sciences, celebrating Australian life science innovations – from groundbreaking research to advanced medical technologies and therapies.
As a super-connector event, it drives critical conversations within our industry, boosting collaboration, informing policy, and creating long-term partnerships that enable Australia’s life sciences ecosystem to thrive.
Built by our industry for our industry, AusBiotech 2026 is a platform to showcase innovation, forge international partnerships, and shape the future of life sciences. The quality of submissions we receive each year reflects the sector’s groundbreaking advancements.
Global visibility
Share your expertise and connect with like-minded professionals on a stage where life science leaders thrive.
Collaboration at scale
Engage with leading minds across borders to inspire new ideas and accelerate powerful partnerships.
Thought leadership
Position yourself or your organisation as a key contributor to industry dialogue and excellence.
Topics of interest and program priorities 2026
Submissions should highlight cutting-edge developments, practical case studies, and forward-looking perspectives. These priorities are intended as a guide rather than a limitation, and we welcome ideas that cut across multiple areas or introduce new perspectives.
All proposals must be submitted by 1 May 2026.
Global partnering and collaboration
Cross‑border partnerships, international collaboration models, and strategies for engaging with global industry, research and government partners.
Investment and capital pathways
Global investment trends, attracting international capital, deal‑making, partnering models, and perspectives from domestic and international investors.
Scaling Australian innovation globally
Pathways for Australian companies to access and succeed in global markets, including commercialisation, market entry strategies and lessons from companies that have scaled internationally.
Regulatory, policy and market access
Navigating international regulatory environments, reimbursement and health system access, and policy settings that enable global competitiveness.
Manufacturing, supply chains and sovereign capability
Global manufacturing strategies, resilience and diversification of supply chains, and Australia’s role in regional and global manufacturing ecosystems.
Emerging technologies with global application
Platform technologies, converging sciences and innovations with the potential for global impact across biotech, medtech and digital health.
Submission Guidelines
01
Format
We invite proposals for presentations, panel discussions, workshops, or other engaging formats suited to your topic.
02
Content
Emphasise evidence-based insights, actionable strategies, and clear impact. Avoid marketing-focused or purely promotional content.
03
Abstract
Provide a concise summary (300 words max), highlighting the core message, methodology, and anticipated outcomes for attendees.
04
Deadline
All proposals must be submitted by 1 May 2026.
Selection Criteria
Proposals will be evaluated based on:
01
Relevance
Alignment with current trends, research, and challenges in biotechnology and life sciences.
02
Originality
Novel approaches or fresh insights that stimulate thought and discussion.
03
Applicability
Actionable knowledge that can be readily adopted or inform future collaborations.
04
Clarity
Well-organised and concise abstracts demonstrating rigour and impact.
Please note
AusBiotech Conference in a cross disciplinary industry conference covering development in the life science industry rather than a scientific conference. Submissions will be considered by AusBiotech in respect to the overarching conference vision and will be assessed against current priorities in the industry.
AusBiotech is committed to diversity and inclusion and submissions for panels will only be considered if they meet a 50% female representation threshold.